Roivant Sciences Ltd. — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended September 30, 2023 (Roivant fiscal Q2 2024), not 2022 Q2 as stated in the request metadata. Financial statements are unaudited; amounts below are in U.S. dollars.
Business context and reporting period
Roivant is a commercial-stage biopharmaceutical company that develops and commercializes medicines through majority-owned and affiliated “Vants.” Its portfolio includes VTAMA (tapinarof), approved in the U.S. for adult plaque psoriasis, and clinical-stage programs including batoclimab, IMVT-1402, brepocitinib and RVT-3101. The company reports one consolidated operating segment.
Key financial metrics
| Metric | Three months ended Sep. 30, 2023 | Three months ended Sep. 30, 2022 | Six months ended Sep. 30, 2023 | Six months ended Sep. 30, 2022 |
|---|---|---|---|---|
| Product revenue, net | $18.4m | $5.0m | $35.1m | $5.1m |
| License, milestone and other revenue | $18.7m | $7.6m | $23.6m | $11.7m |
| Total revenue | $37.1m | $12.5m | $58.7m | $16.9m |
| Operating loss | $(276.5)m | $(280.8)m | $(552.9)m | $(563.1)m |
| Net loss | $(331.1)m | $(315.9)m | $(659.0)m | $(669.7)m |
| Net loss attributable to Roivant | $(304.3)m | $(291.6)m | $(596.1)m | $(623.4)m |
| Basic and diluted loss per share | $(0.40) | $(0.42) | $(0.78) | $(0.89) |
Margins and expenses: Second-quarter cost of revenue was $3.3m against total revenue of $37.1m; the filing does not provide a directly comparable product-only gross margin. R&D was $132.0m for the quarter and $257.1m for six months. SG&A was $164.4m and $320.5m, respectively. Acquired in-process R&D expense was $14.0m for the quarter and $26.5m for six months.
Cash flow and liquidity: At September 30, cash and cash equivalents were $1.408bn; cash, cash equivalents and restricted cash totaled $1.423bn. Six-month operating cash use was $446.4m, investing cash use $36.3m and financing cash inflow $215.3m. Management stated existing cash was expected to fund committed operating expenses and capital expenditure requirements for at least 12 months from issuance of the statements.
Debt and balance sheet: Current and noncurrent debt totaled approximately $438.4m at September 30, compared with approximately $416.2m at March 31, 2023. Total current liabilities were $265.5m and total assets were $2.066bn. Cash declined from $1.677bn at March 31. Roivant raised approximately $199.8m net in a September share offering.
Material changes versus the prior comparable period
- Quarterly total revenue rose to $37.1m from $12.5m, primarily as VTAMA sales grew and Dermavant recognized a $15.0m milestone under its Japan Tobacco collaboration. Six-month revenue increased to $58.7m from $16.9m.
- Quarterly operating loss narrowed modestly, but net loss attributable to Roivant increased to $304.3m from $291.6m. For the six-month period, both consolidated net loss and Roivant-attributable loss improved year over year.
- Six-month R&D declined by $10.7m, principally reflecting lower spending on other development and discovery programs, partly offset by increased anti-FcRn and RVT-3101 spending. SG&A increased by $13.8m for six months, mainly due to VTAMA commercialization costs.
- Higher interest income partly reflected higher rates on invested cash. Fair-value losses on debt and liability instruments were $76.0m for six months, versus $27.7m a year earlier; fair-value losses on investments were $53.4m versus $79.2m.
- Roivant deconsolidated VantAI and Proteovant following transactions in July and August 2023, recording a $17.4m gain. It received $47.5m from the Proteovant sale and retained an investment in VantAI.
Outlook, management commentary, risks and unusual items
- Roche transaction, subsequent event: In October 2023, Roche agreed to acquire Telavant for $7.1bn cash at closing, subject to customary adjustments, plus a $150m payment upon initiation of a Phase 3 ulcerative colitis trial. Roivant expected to receive about $5.2bn at closing and could receive about $110m of the milestone. Closing was expected in Q4 2023 or Q1 2024, subject to regulatory and other conditions; proceeds were not part of September 30 cash.
- Immunovant financing, subsequent event: Immunovant’s October offering and concurrent private placement generated approximately $466.6m net proceeds to Immunovant. Roivant stated it would continue consolidating Immunovant and held about 55% ownership following the financing.
- Pipeline and spending: Management anticipated continued investment in clinical development, discovery and VTAMA commercialization, and expected R&D and SG&A costs to increase. Listed expected catalysts included IMVT-1402 data, brepocitinib lupus data, batoclimab Graves’ disease data and a VTAMA atopic dermatitis supplemental filing; timings were estimates and subject to change.
- New license: A July 2023 asset acquisition included a $14.0m upfront payment expensed as IPR&D, potential future development, regulatory and commercial milestones of up to $280m, and tiered high-single-digit sales royalties.
- Commercial obligations: Minimum purchase commitments included approximately $42.6m for VTAMA supply and $18.7m for batoclimab manufacturing; Palantir software subscription minimum payments were $19.1m. Additional contingent milestone and royalty obligations may arise under license and acquisition agreements.
- Legal and development risks: The filing describes ongoing patent litigation involving Genevant/Arbutus and Moderna and Pfizer/BioNTech, and a re-filed Acuitas declaratory action. An Immunovant securities class action remained pending; Roivant recorded no liability because it could not reasonably estimate potential losses or determine their likelihood. Clinical, regulatory, manufacturing, reimbursement, intellectual-property and financing uncertainties remain significant.
- Other unusual items: Warrants were redeemed or exercised cashlessly in 2023, resulting in share issuance and changes in fair-value liabilities. Roivant reported 800.8m common shares outstanding at September 30 and 803.9m as of November 9. Management concluded disclosure controls were effective at September 30; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Whether and when the Roche–Telavant transaction closed, the final proceeds to Roivant, and the status and conditions of the $110m potential milestone.
- VTAMA prescription growth, net pricing and gross-to-net deductions, payer access, commercial spending and progress toward sustainable product economics.
- Cash burn and financing needs relative to the company’s stated minimum 12-month liquidity expectation, including the effect of Immunovant’s financing and any transaction proceeds.
- Debt repayment terms and future payment obligations under the NovaQuest facility, revenue-interest agreement and other subsidiary debt.
- Clinical data, regulatory timelines and spending for key programs, particularly IMVT-1402, batoclimab, brepocitinib and VTAMA in atopic dermatitis.
- Potential outcomes and financial exposure from the disclosed litigation, as well as contingent milestones, royalties and supply commitments.